Show simple item record

dc.contributor.authorChandrashekar, M
dc.contributor.authorPhilip, S
dc.contributor.authorNesbitt, A
dc.contributor.authorJoshi, A
dc.contributor.authorPerera, M
dc.date.accessioned2021-10-11T06:28:32Z
dc.date.available2021-10-11T06:28:32Z
dc.date.issued2021
dc.identifier.issn0919-8172
dc.identifier.doi10.1111/iju.14624
dc.identifier.urihttp://hdl.handle.net/10072/408819
dc.description.abstractSodium glucose-linked transport protein 2 inhibitors are relatively novel drugs, used for the treatment of type 2 diabetes mellitus. Their use since Pharmaceutical Benefits Scheme approval in Australia has increased drastically, possibly due to the low risk of hypoglycemic events and their advertised cardiovascular mortality benefits. However, as with any novel drug, adverse effects regarding their use require medical practitioner awareness for optimal patient outcomes. This paper aims to cover the major urological implications, including those pertinent perioperatively, that concern this class of drugs. There is a clear risk of developing genital mycotic infections with the use of sodium glucose-linked transport protein 2 inhibitors, including serious infections such as Fournier’s gangrene. Evidence for developing urinary tract infections has been mixed. Sodium glucose-linked transport protein 2 inhibitor-induced lower urinary tract symptoms may have impacts on quality of life via pollakiuria and nocturia, of which there are increased reports. Perioperative use increases the risk of euglycemic diabetic ketoacidosis. It is recommended that sodium glucose-linked transport protein 2 inhibitors be ceased perioperatively.
dc.description.peerreviewedYes
dc.languageen
dc.publisherWiley
dc.relation.ispartofjournalInternational Journal of Urology
dc.subject.fieldofresearchEndocrinology
dc.subject.fieldofresearchNephrology and urology
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode320208
dc.subject.fieldofresearchcode320214
dc.subject.fieldofresearchcode3214
dc.subject.fieldofresearchcode3202
dc.titleSodium glucose-linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationChandrashekar, M; Philip, S; Nesbitt, A; Joshi, A; Perera, M, Sodium glucose-linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications, International Journal of Urology, 2021
dc.date.updated2021-10-06T00:39:58Z
gro.description.notepublicThis publication has been entered in Griffith Research Online as an advanced online version.
gro.hasfulltextNo Full Text
gro.griffith.authorNesbitt, Alexander L.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record